Sol,
I wouldn't call 4-5 days later scrambling. I expect a
Sol,
I wouldn't call 4-5 days later scrambling. I expect a very descriptive blog tomorrow.
Like most of his are. Remember, he's the CEO as such he has to be somewhat evasive but the details are usually in there if you hunt for them.
Manipulative is a strong word here and you should rethink using it in this instance. He gave great numbers like he promised. Now was there a change in lowering the data points used? Yes. However, the p value is still phenomenal and so what that he didn't dumb it down for a majority of fools that invest without doing proper dd on ALL the science, myself included. He still gave it to the ones that actually matter the most in this instance. The ones whom will decide if Lympro really succeeds. Of course I'm referring to the KOL's. With out the KOL's seeing and understanding then the share price is just fluff to begin with. Which was shown to be somewhat true. Will that stop it from trending back up before the all the data is released, no.
As you and I, and many other know from this stock or should know by now: sell before the news, during the lead up. Granted this time i really thought it wa going to be the ignition switch we've been waiting for and this got me and many others over excited again. I'm confident in my read on the situation. Once again, believe it or not AMBS got the news/numbers to the ones that matter the most this time and it wasn't the market. It was the people that're going to order the test and demand their clients do it. I'm just excited as hell about the final numbers coming out. You can rest assured that the next set of number will be with market in mind as well.
For the record, I usually respect your reads on this stock. I don't however respect your agenda. This time though I think you got it wrong and I don't see the shares being increased. So stop all that BS until you actually have something to back it up. It's just another example of why folks don't respect you. Maybe a good option would be for you to PM someone before spreading ridiculous unfounded rumors in public. Someone that can hold you accountable before you run crazy with it. If you get evidence of such a thing I would be all ears.
Tomorrow will and should be interesting.
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Look Who's Lining Up for Chinese Pastries Alright, here we go. China's baking scene is pulling in audiences far and wide, as if the whole world suddenly caught a whiff of their freshest, steaming buns. The 11th Bakery China Autumn, recently wrapped up at the Wuhan International Expo Center, saw a 50% rise in international buyers. This stat gives you that warm and cozy...
Continue Reading
TORM Navigates Chaotic Waters With Impressive Earnings Alright, TORM's catching my eye here amidst what seems like a global logistical mess. These folks are proving that chaos can indeed be lucrative. Cranking out robust numbers in Q3 2026, they've managed to steer through the murky oil trade waters carved by US-Iran tensions. We're seeing TORM's time charter equivalent...
Continue Reading
Stellus Capital's Upcoming Financial Reveal: Stakes and Details November's not just bringing the cold breezes, folks; it's also ushering in the much-anticipated financial digits of Stellus Capital Investment Corporation's third quarter of 2026. Mark your calendars for November 9, after the stock market wraps up, when Stellus will drop its operational performance stats for...
Continue Reading
A New Era for Family Entertainment Centers Forget the traditional FEC with its solitary rides; the future's all about constructing social destinations that blend immersive storytelling and hybrid offerings. Elephant Sculpture Art Co., Ltd. (ESAC) is at the forefront, drawing from their Shanghai WUNPARK project to reimagine the design of these amusement hubs. Set to engage...
Continue Reading
VR-1.1 Makes Waves in Cybersecurity Who would've thought the cyber scene was ripe for a shake-up? Well, Cogent Security's VR-1.1 is here to prove that notion dead right. Their latest AI powerhouse has topped the charts, outperforming existing tools like Claude Code and Codex on LiveCVEBench. VR-1.1 clocked in with a 57.9% success rate in patching vulnerabilities in real...
Continue Reading
Diplomacy Takes Center Stage So here we are again, riding the rollercoaster of geopolitics that's jerking the oil market around like a marionette. With the U.S. and Iran allegedly chatting—mind you, with a ton of smoke and mirrors through Qatar and Islamabad—every trader's watching, hoping for a ceasefire that might either stabilize or further jolt energy prices. Oil...
Continue Reading
Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...
Continue Reading
MOBILion Joins Waters' Fold: A New Era for Proteomics Ah, the biotech world just saw another big whirl with Waters Corporation snagging MOBILion Systems. Now, this isn't just some stroll in the market park. We're talking about weaving MOBILion's fancy high-resolution ion mobility separation tech right into Waters' already robust mass spectrometry setup. These folks are...
Continue Reading
A Bold Step Into the Hydrogen Era Hyundai's really stepping it up at the World Hydrogen Expo 2026. They're not just dipping their toes in the hydrogen pool—they're diving in headfirst, showing off integrated hydrogen solutions that are nothing short of ambitious. Hydrogen Production That's a Real Game Changer This ain't just talk. Hyundai's showcasing modular PEM...
Continue Reading
Meteor's Move: AET Labs Picked Up in CTE Plays You see, Meteor Education ain't sitting on its hands, that's for sure. They're out here hoarding strategic pieces like it's a chess match, snatching up AET Labs to bolster their already sturdy CTE playbook. No financial details spilled, but hell, that’s par for the course. This move plants them even more firmly in New...
Continue Reading
Top 5 Most Recently Viewed Articles
JPMorgan's Positive Stance on Carvana Despite Challenges JPMorgan analysts have recently recommended that investors consider buying Carvana (NYSE: CVNA) shares, especially during market weaknesses. This advice comes in light of a critical report issued by Hindenburg Research, a short-seller that has raised questions about the company's performance. Understanding...
Continue Reading
Ravi Chandran Krishnadas Takes the Helm at RWS India Here's a nugget to chew over your coffee: RWS, that AIM-listed powerhouse (RWS.L), just brought in Ravi Chandran Krishnadas as their new heavy hitter in India. Stepping on the scene June 1, 2026, his title is as long as a summer night—Senior Vice President & Country Lead, India. But what it boils down to is, he's...
Continue Reading
West Coast Trial Lawyers Forms Partnership with University of Arizona Athletics Today, West Coast Trial Lawyers (WCTL) proudly announced its official partnership with the University of Arizona Department of Intercollegiate Athletics. This personal injury law firm, recognized for its outstanding record of winning cases, has committed to actively supporting various athletic...
Continue Reading
Hyperscale Data Reports Significant Bitcoin Mining Revenue Growth Hyperscale Data, Inc. (NYSE American: GPUS) has put a spotlight on its impressive performance in Bitcoin mining this year. As of a recent announcement, the firm reported approximately $8.7 million in Bitcoin mining revenue year to date. This figure includes about $1.9 million earned in May alone, showcasing...
Continue Reading
DLT Entertainment Expands Merchandise for Beloved Shows DLT Entertainment, an acclaimed international production house, is making significant strides in enhancing its merchandise offering for fans of the classic sitcom, Three's Company, and its spin-off, The Ropers. This initiative reflects the ever-growing interest from the audience, showcasing the brand's commitment to...
Continue Reading